Artivion (AORT) Q3 2026 Earnings Call Transcript
Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.
How this was made
The 30-second read
Why it matters
The earnings release offers fresh data on revenue growth, margin pressure, and pipeline progress, informing short‑term trading decisions.
Market read
Earnings data directly impacts AORT stock price; sector peers may be indirectly affected.
What to watch
PerClot transaction and upcoming ARCEVO LSA FDA timeline could provide future upside not reflected in current numbers.
Background
Artivion (AORT) held its Q3 2026 earnings call, providing detailed financial and operational updates.
Ticker impact
Artivion reported Q3 2026 earnings with revenue up 9% YoY to $123.8M but adjusted EBITDA down 8% YoY.
potential modest downside as investors weigh EBITDA decline against revenue growth
Revenue beat expectations while EBITDA miss may pressure the stock in the near term.
Market effects
Signals mixed performance for medical device sector; growth in stent grafts may benefit peers.
North America revenue growth supports US medtech outlook.
Limited to medtech investors; no broad market effect.
Counterpoint
Despite revenue growth, the EBITDA decline could indicate deeper cost issues, making the stock a short candidate.
Key entities
- CompanyArtivion
Medical device manufacturer reporting Q3 2026 results.
- ExecutiveLance Berry
Speaker on the earnings call.
